Janetta Trochimiuk was named President and Chief Executive Officer of PDS Biotechnology Corp, effective September 12, 2026. As of November 6, 2026, PDS Biotechnology Corp has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from August 19, 2026 to October 20, 2026, naming 3 appointments (Form 8-K, August 19, 2026).
PDS Biotechnology Corp named a new Director on Sep 14. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like PDS Biotechnology Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Deborah A. Ramsdell · Role: Director · 8-K, 2026-10-20
- · In / out: In · Person: James Banaag · Role: Director · 8-K, 2026-09-14
- · In / out: In · Person: Janetta Trochimiuk · Role: President and Chief Executive Officer · Effective: 2026-09-12 · 8-K, 2026-08-19
PDS Biotechnology Corp reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-08-19 to 2026-10-20. They name 3 people. Every row below is cited to the filing it comes from, and this page adds each new change as PDS Biotechnology Corp files it.
Layoffs on record: 1 filing or notice, latest 2026-08-25 (layoff filings and notices).
Also on the record for PDS Biotechnology Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 21, 2026 | Stake report, Schedule 13D, by Nant Capital, LLC | 19.9% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs PDS Biotechnology Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on PDS Biotechnology Corp and the records around it.
PDS Biotechnology Corp elsewhere on the record
- 5%+ stake filings Sep 2026
- Layoff notices Aug 2026
- Who owns it
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch PDS Biotechnology Corp
Get an email when PDS Biotechnology Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on PDS Biotechnology Corp?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on PDS Biotechnology Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on PDS Biotechnology Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-20 | In | Director | 8-K, 2026-10-20 | ||
| 2026-09-14 | In | Director | 8-K, 2026-09-14 | ||
| 2026-08-19 | In | President and Chief Executive Officer | 2026-09-12 | 8-K, 2026-08-19 |
Who leads PDS Biotechnology Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Deborah A. Ramsdell, appointed (filed 2026-10-20).
- President and Chief Executive Officer: Janetta Trochimiuk, appointed, effective 2026-09-12 (filed 2026-08-19).
New leaders reset buying decisions — get the Full Report on PDS Biotechnology Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at PDS Biotechnology Corp, with the record behind each one.
Find candidates like Director at PDS Biotechnology CorpEvery change, in the filing's words
Appointed: Deborah A. Ramsdell, Director
Election of Directors Following the resignations, on October 18, 2026, the Board appointed Deborah A. Ramsdell, John A. Dawson CBE and Bruce Wendel (each, a " New Director ") as directors of the Company, effective immediately, to fill three of the four vacancies created by the resignations described above.
- Departure of Directors On October 18, 2026, each of Kamil Ali-Jackson, Esq., Stephen Glover, Gregory Freitag, J.D., CPA, and Otis Brawley, M.D. notified the Board of Directors (the "Board") of PDS Biotechnology Corporation (the "Company") of his or her resignation as a member of the Board, and of each committee of the Board on which he or she served, effective immediately.
- None of the resignations was the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Ms. Ramsdell was appointed as a Class A director to serve until the 2027 Annual Meeting of Stockholders and until her successor is duly elected and qualified.
- Mr. Dawson was appointed as a Class B director to serve until the 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified.
- Mr. Wendel was appointed as a Class C director to serve until the 2028 Annual Meeting of Stockholders and until his successor is duly elected and qualified.
- In connection with the appointments, the Board fixed the authorized number of directors constituting the entire Board at seven (7) directors.
- Deborah A. Ramsdell has more than 35 years of experience in leadership roles at early- and clinical-stage biotechnology companies, with a focus on rare disease drug development.
Appointed: James Banaag, Director
Mr. Banaag was appointed as a Class A director of the Company, to serve until the Company's 2028 annual meeting of stockholders or until his earlier death, resignation, removal, or until such time that Nant no longer has the right to designate two Nant Designees pursuant to the terms and conditions of the Purchase Agreement.
- Dr. Soon-Shiong and Mr. Banaag were selected as directors pursuant to the board designation rights set forth in Section 5.14 of the Purchase Agreement, which provides that Nant Capital, LLC and its affiliates (collectively, "Nant") have the right to designate two individuals (the "Nant Designees") to be appointed to the Board for so long as Nant beneficially owns fifteen percent (15%) or more of the Company's outstanding Common Stock.
- Dr. Soon-Shiong, FRCS (C), VACS, age 74, is the founder of ImmunityBio, Inc., a biotechnology company.
- Dr. Soon-Shiong was appointed Executive Chairman of the Board of ImmunityBio, Inc. in October 2020 and Global Chief Scientific and Medical Officer of the company on August 11, 2021.
- Previously, he served as the Chairman of the Board and Chief Executive Officer from March 2015 to October 2020, as the Co-Chairman of the board of directors from December 2014 to March 2015, and as the Chief Medical Officer of ImmunityBio, Inc. from January 2015 to March 2015.
- In 2011, he founded NantWorks, LLC ("NantWorks"), an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information.
Appointed: Janetta Trochimiuk, President and Chief Executive Officer, effective 2026-09-12
On August 19, 2026, the board of directors of the Company appointed Janetta Trochimiuk, the Company's Controller, as interim Principal Accounting Officer and Frank Bedu-Addo, Ph.D., the Company's President and Chief Executive Officer, as interim Principal Financial Officer, each effective as of September 12, 2026.
- On August 13, 2026, Lars Boesgaard submitted his resignation, effective as of September 12, 2026, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corporation (the "Company") in order to pursue other professional endeavors.
- Mr. Boesgaard acknowledged that his resignation is not the result of any disagreement relating to Company's operations, policies or practices.
- Ms. Trochimiuk, age 63, joined the Company as Controller in December 2019.
- Ms. Trochimiuk has more than 25 years of experience as a Controller or Chief Financial Officer at various corporations.
- Prior to joining the Company, Ms. Trochimiuk served as Controller at Delcath Systems, Inc., located in New York, New York from April 2017 to July 2019, Controller and Chief Financial Officer of Westwood Consulting Group, LLC from October 2012 to January 2017, regional Chief Financial Officer at Ceragon Networks, Inc. from January 2009 to October 2012, and Controller North America at Olam Americas, Inc. from November 2005 to September 2007.
- Ms. Trochimiuk holds a Bachelor of Business Administration from Bernard M. Baruch College and is a licensed CPA.
- Ms. Trochimiuk will continue to receive a base salary of $279,519.57 per year and will continue to be eligible for equity awards under the Company's Third Amended and Restated 2014 Equity Incentive Plan.
Tools for this story
Each opens in a new tab, filled in for PDS Biotechnology Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.